Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR | P30559 | 1/20 | 0.46 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 12/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 11/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 10/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5768740 | 0.81 | HTR2C (0.48) | OXTRAVPR1AOPRM1OPRK1OPRL1 | |
| SCHEMBL14486768 | 0.81 | OPRM1 (0.52) | OXTRAVPR1AOPRM1OPRK1OPRL1 | |
| SCHEMBL14410177 | 0.81 | OXTR (0.47) | OXTRAVPR1AOPRM1OPRK1OPRL1 | |
| SCHEMBL3959841 | 0.80 | OXTR (0.53) | OXTRAVPR1A | |
| SCHEMBL7447387 | 0.79 | OPRL1 (0.69) | OXTRAVPR1AOPRM1OPRK1OPRL1 | |
| Hydrochloric Acid SCHEMBL8863969 | 0.79 | OPRM1 (0.51) | OXTRAVPR1AOPRM1OPRK1OPRL1 | |
| SCHEMBL17525073 | 0.78 | OXTR (0.43) | OXTRAVPR1AOPRM1OPRK1OPRL1 | |
| SCHEMBL17525104 | 0.78 | GFER (0.44) | OXTRAVPR1AOPRM1OPRK1OPRL1 | |
| SCHEMBL6247970 | 0.75 | OXTR (0.49) | OXTRAVPR1A | |
| SCHEMBL6247351 | 0.74 | OXTR (0.53) | OXTRAVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163480-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | DR. KARL THOMAE GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
| US-20090163480-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | DR. KARL THOMAE GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
| US-7498325-B2 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | KARL THOMAS GMBH (DE) | 2009-03-03 | — | — | US | disclosed |
| US-7498325-B2 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | KARL THOMAS GMBH (DE) | 2009-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163480-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | PTMS, CHRM1, SRMS | OXTR 62/4885AVPR1A 56/4885OPRM1 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.